Literature DB >> 16548770

Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders.

K Yaragudri Vinod1, Basalingappa L Hungund.   

Abstract

G-protein-coupled receptor (GPCR)-mediated signalling is the most widely used signalling mechanism in cells, and its regulation is important for various physiological functions. The cannabinoid-1 (CB(1)) receptor, a GPCR, has been shown to play a critical role in neural circuitries mediating motivation, mood and emotional behaviours. Several recent studies have indicated that impairment of CB(1) receptor-mediated signalling may play a critical role in the pathophysiology of various neuropsychiatric disorders. In this article, the authors briefly review literature relating to the role played by the endocannabinoid system in various neuropsychiatric disorders, and the CB(1) receptor as a potential therapeutic target for the treatment of alcoholism, depression, anxiety and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16548770     DOI: 10.1517/14728222.10.2.203

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  12 in total

Review 1.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

2.  Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study.

Authors:  Laura Kranaster; Carolin Hoyer; Suna Su Aksay; Jan Malte Bumb; F Markus Leweke; Christoph Janke; Manfred Thiel; Beat Lutz; Laura Bindila; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-24       Impact factor: 5.270

3.  Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression.

Authors:  D Koethe; I C Llenos; J R Dulay; C Hoyer; E F Torrey; F M Leweke; S Weis
Journal:  J Neural Transm (Vienna)       Date:  2007-03-19       Impact factor: 3.575

4.  Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.

Authors:  Andrea Balla; Bin Dong; Borehalli M Shilpa; Kiran Vemuri; Alexandros Makriyannis; Subhash C Pandey; Henry Sershen; Raymond F Suckow; K Yaragudri Vinod
Journal:  Neuropharmacology       Date:  2017-11-03       Impact factor: 5.250

5.  Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence.

Authors:  Alexander Neumeister; Marc D Normandin; James W Murrough; Shannan Henry; Christopher R Bailey; David A Luckenbaugh; Keri Tuit; Ming-Qiang Zheng; Isaac R Galatzer-Levy; Rajita Sinha; Richard E Carson; Marc N Potenza; Yiyun Huang
Journal:  Alcohol Clin Exp Res       Date:  2012-05-02       Impact factor: 3.455

6.  Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population.

Authors:  Kristin S Cadenhead
Journal:  Psychiatry Res       Date:  2011-05-08       Impact factor: 3.222

7.  No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.

Authors:  Chao Deng; Mei Han; Xu-Feng Huang
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

8.  Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice.

Authors:  K Yaragudri Vinod; Ratnakumar Yalamanchili; Panayotis K Thanos; Csaba Vadasz; Thomas B Cooper; Nora D Volkow; Basalingappa L Hungund
Journal:  Synapse       Date:  2008-08       Impact factor: 2.562

9.  Altering endocannabinoid neurotransmission at critical developmental ages: impact on rodent emotionality and cognitive performance.

Authors:  Viviana Trezza; Patrizia Campolongo; Antonia Manduca; Maria Morena; Maura Palmery; Louk J M J Vanderschuren; Vincenzo Cuomo
Journal:  Front Behav Neurosci       Date:  2012-01-24       Impact factor: 3.558

10.  CB1 receptor neutral antagonist treatment epigenetically increases neuropeptide Y expression and decreases alcohol drinking.

Authors:  Russell S Dulman; Huaibo Zhang; Ritabrata Banerjee; Harish R Krishnan; Bin Dong; Basalingappa L Hungund; K Yaragudri Vinod; Subhash C Pandey
Journal:  Neuropharmacology       Date:  2021-05-26       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.